RPG Life Sciences

Mumbai, India Founded: 1968 • Age: 58 yrs Listed
Generics and APIs are manufactured by RPG Life Sciences.
Request Access
Report Incorrect Data
Page last updated

About RPG Life Sciences

RPG Life Sciences is a publicly listed company based in Mumbai (India) founded in 1968 by Yugal Sikri. Generics and APIs are manufactured by RPG Life Sciences. The company has 1,780 employees. Its website rpglifesciences.com draws about 16 thousand monthly visits. Its Indian entity Rpg Life Sciences Limited reported revenue of ₹758 Cr. Its focus areas include Traditional Pharmaceuticals and Diversified.

Company details

RPG Life Sciences was established in 1968 in Mumbai, India, as a biopharmaceutical entity. Branded formulations, generics, synthetic APIs, and fermented APIs are produced, with focus on therapeutic areas such as immunosuppressants, antidepressants, anticancer agents, and antihelminthics. Domestic operations are segmented into nephrocare for kidney products, neolife for oncology, and the LOMO group for antidiarrheal and anticholinergic treatments.

  • Headquarters Mumbai, India
  • Employees 1,780
  • Founders Yugal Sikri
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website rpglifesciences.com
  • Social LinkedIn X Facebook
  • Legal Name Rpg Life Sciences Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹4,260 Cr

    RPGLIFE · NSE

  • Share Price
    ₹2,549.50

    -1.02% today

  • Revenue
    ₹708 Cr

    FY 2025-26 · +8.3% YoY

  • EBITDA
    ₹127 Cr

    Margin 18.0%

  • Net Profit
    ₹110 Cr

    FY 2025-26 · -5.1% YoY

  • P/E (TTM)
    37.1x

    P/B 6.2x

  • ROE
    20.3%

    ROCE 26.6%

  • Debt / Equity
    0.02

    Interest cover 1.7x

  • Employee Count
    1,780

Board of directors of Rpg Life Sciences Limited (RPG Life Sciences)

Rpg Life Sciences Limited is the primary company behind RPG Life Sciences. The board of Rpg Life Sciences Limited currently have 13 directors; the longest-serving is Manojkumar Madangopal Maheshwari, appointed in 2008. 23 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Manojkumar Madangopal Maheshwari
DIN 00012341
Director06 Feb 200818 yrs 8 moRpg Life Sciences Limited
Harsh Vardhan Goenka
DIN 00026726
Director06 Feb 200818 yrs 8 moRpg Life Sciences Limited
Sachin Rajkumar Nandgaonkar
DIN 03410739
Director23 Jan 201511 yrs 9 moRpg Life Sciences Limited
Zahabiya Habil Khorakiwala
DIN 00102689
Director29 Oct 201511 yrsRpg Life Sciences Limited
Bhaskar Vemban Iyer
DIN 00480341
Director30 Oct 20197 yrsRpg Life Sciences Limited
Rajat Bhargava
DIN 07752438
Director25 Jan 20215 yrs 9 moRpg Life Sciences Limited
Radhika Gupta
DIN 02657595
Additional Director30 Apr 20242 yrs 6 moRpg Life Sciences Limited
Anilkumar Matai
DIN 03122685
Additional Director30 Apr 20242 yrs 6 moRpg Life Sciences Limited
Hiten Kantilal Kotak
DIN 00191115
Additional Director30 Apr 20242 yrs 6 moRpg Life Sciences Limited
Vasundhara Apoorva Patni
DIN 05015021
Director28 Apr 20251 yr 6 moRpg Life Sciences Limited
Yugal Kishor Chothuram Sikri
DIN 07576560
Director01 May 20251 yr 6 moRpg Life Sciences Limited
Ashok Nair
DIN 07906710
Managing Director01 May 20251 yr 6 moRpg Life Sciences Limited
Pratit Prahalad Samdani
DIN 10139232
Additional Director29 Apr 20266 moRpg Life Sciences Limited

People of RPG Life Sciences

9 people are tracked at RPG Life Sciences (1 in leadership, 8 in board & advisors); the tracked headcount is 1,780.

NameRoleGroup
Yugal Sikri
FounderLeadership
Bhaskar Iyer
Independent and Non-Executive DirectorBoard & advisors
Rajat Bhargava
Non-Executive DirectorBoard & advisors
Lalit Kanodia
Independent and Non-Executive DirectorBoard & advisors
Mahesh Gupta
Independent and Non-Executive DirectorBoard & advisors
Narendra Ambwani
Independent and Non-Executive DirectorBoard & advisors
Manoj Maheshwari
Independent and Non-Executive DirectorBoard & advisors
Zahabiya Khorakiwala
Independent and Non-Executive DirectorBoard & advisors
Sachin Nandgaonkar
Non-Executive DirectorBoard & advisors
Premium access

Complete people profiles for RPG Life Sciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of RPG Life Sciences

RPG Life Sciences is a publicly listed company on the NSE with ticker symbol RPGLIFE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date10 Jun 2008
  • Listed onBSE: 532983 · NSE: RPGLIFE
  • Listed entityRPG Life Sciences Limited
  • Exchange sectorHealth technology
  • ISININE105J01010
  • Share price₹2,812.40 (+0.21% on the day) · 2026-10-14
  • Market capitalisation₹4,647 Cr
  • Price to earnings38.9
  • EPS (diluted, trailing year)₹72.34
  • Dividend yield0.84%
  • Volume (last session)3,110

Financials of RPG Life Sciences

Exchange-reported figures of Rpg Life Sciences Limited, the listed company behind RPG Life Sciences (NSE: RPGLIFE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹708 Cr
+8.3% YoY
EBITDA
₹127 Cr
-11.9% YoY
Profit After Tax
₹110 Cr
-5.1% YoY
Net Worth
₹605 Cr
+14.1% YoY
Total Assets
₹636 Cr
+18.3% YoY
Total Debt
₹20.00 Cr

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25
Income statement
Revenue708653
Revenue growth+8.3%-
EBITDA127144
EBITDA margin+18.0%+22.1%
Profit before tax154233
Net profit110116
Net profit margin+15.5%+17.7%
EPS (₹)69.64110.80
Balance sheet
Total assets636538
Net worth605531
Total debt20.000.00
Cash & bank192140
Net working capital322220
Cash flow
Cash from operations56.5077.86
Cash from investing85.84(41.80)
Cash from financing(20.58)(27.08)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue212196177180182169143173
Revenue growth (YoY)+16.5%+15.9%+23.6%+4.2%----
Other income4.264.1613.503.4115.765.231153.31
EBITDA40.4243.5932.8331.3439.0335.4725.4949.16
EBITDA margin+19.1%+22.3%+18.6%+17.4%+21.5%+21.0%+17.8%+28.5%
Depreciation6.805.905.745.385.225.145.375.46
Interest0.840.630.390.250.120.130.180.12
Profit before tax37.0441.2240.2029.1249.4535.4313546.89
Tax8.8210.6410.306.9912.609.1417.5511.96
Net profit28.2230.5829.9022.1336.8526.2911734.93
EPS (₹)17.0718.4918.0813.3822.2815.9070.9621.12
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue708653582513440389376
Revenue growth+8.3%+12.3%+13.5%+16.5%+13.1%+3.6%-
EBITDA12714412910487.2570.9354.84
EBITDA margin+18.0%+22.1%+22.2%+20.2%+19.8%+18.2%+14.6%
Profit before tax15423311891.6873.1753.5836.45
Net profit11011686.8968.2150.8740.0132.94
Net profit margin+15.5%+17.7%+14.9%+13.3%+11.6%+10.3%+8.8%
EPS (₹)69.64110.8053.0140.9031.1324.1917.54
Balance sheet
Total assets636538382315263225194
Net worth605531375308256216177
Total debt20.000.000.000.010.942.0211.72
Cash & bank15714036.4757.0470.2640.751.11
Net working capital28722076.9810312797.4453.39
Cash flow
Cash from operations56.5077.8694.3690.8264.7558.2750.17
Cash from investing51.06(41.80)(79.15)(106)(34.66)(7.96)(10.70)
Cash from financing(20.58)(27.08)(20.31)(17.12)(13.51)(10.49)(39.30)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue193196177180182169143173
Revenue growth (YoY)+6.5%+15.9%+23.6%+4.2%+5.5%+2.1%--
Other income3.774.1613.463.4115.765.231153.31
Total expenses161152144149143133118124
EBITDA32.6543.5832.8731.3439.0335.4725.4949.16
EBITDA margin+16.9%+22.3%+18.6%+17.4%+21.5%+21.0%+17.8%+28.5%
Depreciation5.565.905.745.385.225.145.375.46
Interest0.780.630.390.250.120.130.180.12
Profit before tax30.0841.2140.2029.1249.4535.4313546.89
Tax6.7910.6410.306.9912.609.1417.5511.96

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue212196177180182169143173
Revenue growth (YoY)+16.5%+15.9%+23.6%+4.2%----
Other income4.264.1613.503.4115.765.231153.31
EBITDA40.4243.5932.8331.3439.0335.4725.4949.16
EBITDA margin+19.1%+22.3%+18.6%+17.4%+21.5%+21.0%+17.8%+28.5%
Depreciation6.805.905.745.385.225.145.375.46
Interest0.840.630.390.250.120.130.180.12
Profit before tax37.0441.2240.2029.1249.4535.4313546.89
Tax8.8210.6410.306.9912.609.1417.5511.96
Net profit28.2230.5829.9022.1336.8526.2911734.93
EPS (₹)17.0718.4918.0813.3822.2815.9070.9621.12
ParticularsFY 2025-26FY 2024-25
Revenue708653
Revenue growth+8.3%-
Other income50.33112
Total expenses580509
Employee cost141126
EBITDA127144
EBITDA margin+18.0%+22.1%
Depreciation21.4821.43
Interest1.771.59
Profit before tax154233
Tax39.0349.64
Net profit110116
Net profit margin+15.5%+17.7%
EPS (₹)69.64110.80
ParticularsFY 2025-26FY 2024-25
Equity & liabilities
Share capital13.2313.23
Reserves & surplus592517
Shareholders' funds (net worth)605531
Minority interest0.000.00
Secured loans20.000.00
Unsecured loans0.000.00
Total debt20.000.00
Total liabilities636538
Assets
Gross block321276
Net block197172
Capital work in progress23.2916.06
Investments84.91127
Inventories12492.98
Sundry debtors11786.76
Cash & bank balances192140
Loans & advances43.5020.00
Total current assets476339
Total current liabilities154120
Net working capital322220
Total assets636538
ParticularsFY 2025-26FY 2024-25
Opening cash28.7019.72
Net cash from operating activities56.5077.86
Net cash from investing activities85.84(41.80)
Net cash from financing activities(20.58)(27.08)
Net change in cash1228.98
Closing cash192140
ParticularsFY 2025-26FY 2024-25
Growth
Sales growth+8.3%-
EBITDA growth-11.9%-
PBT growth-33.8%+9997.0%
Net income growth-5.1%-
Profitability & leverage
Net income margin+16.3%+28.0%
Return on capital employed+26.6%+27.6%
Return on net worth+20.3%+21.8%
Debt / equity0.020.00
Long-term debt / equity0.010.00
Interest cover1.681.29
Efficiency & per share
Fixed asset turnover2.372.37
Inventory turnover6.537.03
Debtors turnover6.967.53
EPS (₹)69.64110.80
Dividend per share (₹)24.0024.00
Book value per share (₹)366.05320.80
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue193196177180182169143173
Revenue growth (YoY)+6.5%+15.9%+23.6%+4.2%+5.5%+2.1%--
Other income3.774.1613.463.4115.765.231153.31
Total expenses161152144149143133118124
EBITDA32.6543.5832.8731.3439.0335.4725.4949.16
EBITDA margin+16.9%+22.3%+18.6%+17.4%+21.5%+21.0%+17.8%+28.5%
Depreciation5.565.905.745.385.225.145.375.46
Interest0.780.630.390.250.120.130.180.12
Profit before tax30.0841.2140.2029.1249.4535.4313546.89
Tax6.7910.6410.306.9912.609.1417.5511.96
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue708653582513440389376
Revenue growth+8.3%+12.3%+13.5%+16.5%+13.1%+3.6%-
Other income50.291127.214.802.990.910.73
Total expenses580509453409353318321
Employee cost14112613211799.9794.6690.97
EBITDA12714412910487.2570.9354.84
EBITDA margin+18.0%+22.1%+22.2%+20.2%+19.8%+18.2%+14.6%
Depreciation21.4821.4317.0715.5015.6616.4716.36
Interest1.771.591.441.151.411.792.76
Profit before tax15423311891.6873.1753.5836.45
Tax39.0349.6430.1824.0421.6913.587.44
Net profit11011686.8968.2150.8740.0132.94
Net profit margin+15.5%+17.7%+14.9%+13.3%+11.6%+10.3%+8.8%
EPS (₹)69.64110.8053.0140.9031.1324.1917.54
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.2313.2313.2313.2313.2313.2313.23
Reserves & surplus592517362294243203163
Shareholders' funds (net worth)605531375308256216177
Secured loans20.000.000.000.010.220.266.52
Unsecured loans0.000.000.000.000.721.765.20
Total debt20.000.000.000.010.942.0211.72
Total liabilities636538382315263225194
Assets
Gross block321276222220186180174
Net block197172114124104113123
Capital work in progress23.2916.0696.3125.4431.0611.779.98
Investments12012791.1658.430.000.000.00
Inventories12492.9810195.0582.9958.3346.61
Sundry debtors11786.7649.1337.4332.9957.4263.33
Cash & bank balances15714036.4757.0470.2640.751.11
Loans & advances43.4920.0021.3416.1020.6719.3514.73
Total current assets441339208206207176126
Total current liabilities15412013110379.4778.4172.39
Net working capital28722076.9810312797.4453.39
Total assets636538382315263225194
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash28.7019.7224.8256.9440.360.540.37
Net cash from operating activities56.5077.8694.3690.8264.7558.2750.17
Net cash from investing activities51.06(41.80)(79.15)(106)(34.66)(7.96)(10.70)
Net cash from financing activities(20.58)(27.08)(20.31)(17.12)(13.51)(10.49)(39.30)
Net change in cash86.988.98(5.10)(32.11)16.5839.820.17
Closing cash15714036.4757.0470.2640.751.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.3%+12.3%+13.5%+16.5%+13.1%+3.6%-
EBITDA growth-11.9%+11.7%+24.7%+18.7%+23.0%+29.3%-
PBT growth-33.8%+97.6%+28.5%+25.3%+36.6%+47.0%+142.2%
Net income growth-5.1%+33.0%+27.4%+34.1%+27.1%+21.5%-
Revenue CAGR (3Y)+11.3%+14.1%+14.4%+10.9%+10.1%+4.2%+8.6%
EBITDA CAGR (3Y)+7.1%+18.3%+22.1%+23.6%+36.3%+22.7%+23.8%
Profitability & leverage
Net income margin+16.3%+28.0%+15.1%+13.2%+11.7%+10.3%+7.7%
Return on capital employed+26.6%+32.3%+34.3%+32.2%+30.6%+26.4%+22.5%
Return on net worth+20.3%+25.5%+25.7%+24.0%+21.8%+20.4%+19.5%
Debt / equity0.020.000.000.000.010.030.14
Long-term debt / equity0.010.000.000.000.000.010.02
Interest cover1.671.291.281.311.973.297.17
Efficiency & per share
Fixed asset turnover2.372.632.642.522.402.202.23
Inventory turnover6.536.745.945.766.237.428.57
Debtors turnover6.969.6213.4514.569.746.457.35
EPS (₹)69.64110.8053.0140.9031.1324.1917.54
Dividend per share (₹)24.0024.0016.0012.009.607.204.00
Book value per share (₹)366.06320.80226.67186.00154.66130.88106.77

Web traffic of RPG Life Sciences

The website of RPG Life Sciences (rpglifesciences.com) receives about 16.5K visits a month.

  • Monthly visits
    16.5K

    ▲ 114.9% vs previous month

Similar websites

Websites whose visitors overlap most with RPG Life Sciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Woodburn Fertilizer
woodburnfertilizer.com
100%
View details
rlssecure.com
rlssecure.com
100%
–
Suntton
suntton.com
100%
View details
Azomures
azomures.com
100%
2.2KView details
Gujrat State Fertilizers and Chemicals
gsfclimited.com
100%
27.2K#904,467View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for RPG Life Sciences

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as RPG Life Sciences (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Rpg Life Sciences

RPG Life: No Significant Effect On Manufacturing Costs Of Oncology Drugs - Interview
Exchange Update • 3 days ago
RPG Life: Reports Gross Margin Improved By 260 Basis Points Year Over Year In Challenging Conditions - Interview
Exchange Update • 3 days ago
RPGLIFE: Q2 SL NET PROFIT 233M RUPEES VS 369M (YOY)
Exchange Update • 4 days ago
RPGLIFE: Q2 EBITDA 326M RUPEES VS 390M (YOY); Q2 EBITDA MARGIN 16.88% VS 21.48% (YOY)
Exchange Update • 4 days ago
RPGLIFE: Q2 EBITDA 326M RUPEES VS 390M (YOY); Q2 EBITDA MARGIN 16.88% VS 21.48% (YOY)
Exchange Update • 4 days ago
RPG Life Sciences: Subsidiary RPG Active Pharma Gets Approval to Merge Actis Generics to Streamline Operations, Cut Costs, and Boost Efficiency.
Exchange Update • 1 month ago
RPG Life Sciences: Plans Meeting With Analysts And Investors On September 22 At 10 AM
Exchange Update • 1 month ago
RPG Life Sciences to deploy Rs 500 crore in next 12 months to bolster manufacturing, API capabilities - The Economic Times
Economic Times • 1 month ago
RPG Life Sciences bets on China-plus 1, goes on an API buying spree | Company Business News
mint • 1 month ago
RPG Life Sciences acquires API and Intermediates biz of Raghava Life Sciences | Capital Market News - Business Standard
Business Standard • 2 months ago
Premium access

Complete news archive for RPG Life Sciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about RPG Life Sciences

RPG Life Sciences was founded in 1968.

RPG Life Sciences is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

RPG Life Sciences has 1,780 employees.

The primary company behind RPG Life Sciences, Rpg Life Sciences Limited, reported revenue of ₹758 Cr for FY 2026, up 8% year on year.

RPG Life Sciences was established in 1968 in Mumbai, India, as a biopharmaceutical entity. Branded formulations, generics, synthetic APIs, and fermented APIs are produced, with focus on therapeutic areas such as immunosuppressants, antidepressants, anticancer agents, and antihelminthics. Domestic operations are segmented into nephrocare for kidney products, neolife for oncology, and the LOMO group for antidiarrheal and anticholinergic treatments.

Yes, RPG Life Sciences is publicly traded on NSE under the ticker symbol RPGLIFE.

RPG Life Sciences operates through Rpg Life Sciences Limited.

The legal entities of RPG Life Sciences currently have 15 directors, including Manojkumar Madangopal Maheshwari, Yugal Kishor Chothuram Sikri, Harsh Vardhan Goenka and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available